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Abstract 
Background 
Chronic kidney disease (CKD) is an established risk factor for incident 
cardiovascular disease and progression of heart failure disease state, and is 
associated with decreased survival after left ventricular assist device (LVAD) 
therapy or heart transplantation (HT). Combined heart-kidney transplantation 
(HKT) compared with isolated HT recently has been shown to have survival 
advantage among patients whose estimated glomerular filtration rate is less than 
37 ml/min/m2. Data on LVAD to HKT are limited. 
Methods 
At our center, a total of 803 patients have received HT, 594 patients LVAD 
therapy, and 23 patients HKT from single donors; of those 23, 15 were without the 
use of LVAD and 8 were after support with LVAD. 
Results 
Kaplan-Meier survival analysis found LVAD-supported patients with CKD stages 4 
or 5 had statistically worse 24-month survival after HT as compared with those 
with CKD stage 1, 2, and 3 (58% versus 88%, p=0.01). Patients who received 
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combined HKT after LVAD had comparable 24-month survival with those who 
received HKT without LVAD (87% and 85%, p=NS); both groups had numerically 
better survival compared with those who had CKD (stage 4-5) with isolated HT 
(58%). 
Conclusions 
Patients supported with LVAD who demonstrate advanced CKD (stage 4-5) have 
worse 24-month post-HT survival compared with those with less advanced CKD 
(stage 1-3). Combined HKT after LVAD support is feasible and confers 
comparable 24-month survival compared with HKT without prior LVAD therapy. 
Our study supports combined HKT for select LVAD patients with advanced CKD 
(stage 4-5). 
Keywords:  Left ventricular assist device, heart transplant, chronic kidney disease 
 
Introduction 
Chronic kidney disease (CKD) as reflected by a lower estimated glomerular 
filtration rate (eGFR) is a strong and independent risk factor for both incident 
cardiovascular disease and subsequent cardiovascular morbidity and mortality.1-3 
Among heart failure patients, lower eGFR is associated with worsening functional 
capacity4,5 and nearly double the risk of 12-month hospitalizations or death.6,7 
Accordingly, measures of renal function used to develop a variety of acute and 
chronic heart failure models confers a proportionally higher risk than many other 
common clinical variables.8-10 Patients with heart failure who have deterioration of 
renal function exhibit impaired neurohormonal activation, abnormal central 
hemodynamics, and reduced cardiac perfusion to the kidneys, commonly 
described as cardiorenal syndrome (CRS).11,12 The identification and, especially, 
the irreversibility of CRS can signify a clinical spiral characterized by worsening 
functional capacity, intolerance to conventional heart failure therapy, and 
increased heart failure-related death – a state, often termed advanced heart 
failure, in which heart replacement options (left ventricular assist device [LVAD] 
therapy or heart transplantation [HT]) are advocated. 
LVAD therapy is an excellent treatment option for patients with advanced heart 
failure, providing substantive improvements in both quality and quantity of life.13-17 
Clinical trials and INTERMACs data have consistently demonstrated that a high 
proportion of patients receiving LVAD therapy have CKD.18,19 Unfortunately, 
advanced CKD (stages 3-5) at the time of heart replacement option is a strong 
independent predictor of worse 12-month survival with either HT or LVAD.20,21 
Most recently, an analysis of the United Network of Organ Sharing (UNOS) 
database demonstrated a survival advantage to combined heart-kidney 
transplantation (HKT) for heart failure patients with advanced CKD (eGFR<37 
ml/min).22 However, limited data exist on the feasibility of LVAD therapy as a 
bridge to HKT.23,24 We document safety and favorable outcomes on a small 
retrospective cohort of patients who underwent combined HKT after chronic LVAD 
therapy. 
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Methods 
A total of 803 patients underwent HT from 1988-2013; among these, 15 received 
combined HKT. A total of 594 patients underwent LVAD therapy, with 256 patients 
having had an LVAD prior to HT, including 8 patients who received HKT (1991-
2013). Each HKT was from a single donor with all procedures performed at Aurora 
St. Luke’s Medical Center (Milwaukee, WI). This retrospective investigation was 
approved by the institutional review board prior to initiation and chart review. All 
256 patients had complete clinical data and comprised the final cohort for analysis. 
The eGFR was estimated using Modification of Diet in Renal Disease (MDRD) 
formulas, and patients were grouped according to established CKD stages. 
Statistics 
Continuous variables are summarized as mean ± SD and categorical variables are 
presented as frequency and percentage, respectively. Differences in continuous 
and categorical variables were compared using Wilcoxon Rank-Sum tests and 
Pearson chi-square tests, respectively (Table 1). Comparison of survival post-
transplant between the LVAD and no LVAD groups were performed using Kaplan-
Meier curves and Log-Rank test (Figures 1 and 2). 
Table 1. Baseline characteristics of patient population 
 
 
 
LVAD to HT 
(n=256) 
CKD 1-3  
(n=241) 
CKD 4-5  
(n=15) 
p 
LVAD to 
HKT  
(n=8) 
HKT  
no LVAD  
(n=15) 
p 
Age 54±12 54±12 58±9 0.02 54±9.7 56±8.3 NS 
BMI 28±6 28±6 30±7 NS 31±8 27±4.1 NS 
Female 48 (19%) 42 (17%) 5 (33%) 0.02 1 (12%) 6 (40%) 0.03 
AA race 55 (21%) 48 (20%) 7 (47%) NS 3 (38%) 1 (7%) NS 
CAD 132 (52%) 
125 
(52%) 
7 (47%) 0.06 4 (50%) 9 (60%) NS 
eGFR 66±27 69±24 21±11 <0.01 19±14 16±12 <0.01 
Support, 
days 
211±214 212±217 190±155 NS 166±100  NS 
 
CKD, chronic kidney disease; LVAD, left ventricular assist device; HKT, heart-
kidney transplant; BMI, body mass index; AA, African American; CAD, coronary 
artery disease; eGFR, estimated glomerular filtration rate. 
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Figure 1. Two-year Kaplan-Meier curve showing survival among patients with 
chronic kidney disease (CKD) supported with a left ventricular assist device 
(LVAD) (1-3) compared with patients with CKD and no LVAD (4-5). HT, heart 
transplantation. 
 
 
Figure 2. Two-year Kaplan-Meier curve showing survival among patients with 
combined heart-kidney transplantation (HKT) with and without left ventricular 
assist device therapy (LVAD) compared with patients with chronic kidney disease 
(CKD) who undergo heart transplantation (HT) alone (4-5).  
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Results 
Table 1 describes the total cohort of 256 patients; most were young (mean age 
54±12) men (n=208, 81%) with coronary artery disease (n=132, 52%), and the 
majority (94%) had mild CKD (stage 1-3) at the time of HT, with a mean group 
eGFR of 69±24 ml/min. A total of 15 patients had severe CKD (stage 4-5) at the 
time of HT, with a mean group eGFR of 21±11; these patients were older (mean 
age 58±9) and more often female (n=5, 33%). Comparatively, patients receiving 
LVAD to HKT (n=8) vs HKT without LVAD (n=15) were less often female (12% vs 
40%, p=0.03) and had slightly higher eGFR (19±14 vs 16±12). 
Kaplan-Meier survival analysis (Figure 1) found LVAD-supported patients with 
CKD stage 4 or 5 had statistically worse 24-month survival after HT compared with 
those with CKD stage 1, 2, or 3 (58% vs 88%, p=0.01). Patients who received 
combined HKT after LVAD had comparable 24-month survival with those that 
received HKT without LVAD (87% and 85%, p=NS); both groups had numerically 
better survival compared with those who had CKD (stages 4 or 5) with isolated HT 
(58%). 
Discussion 
Higher CKD stage, characterized by lower eGFR, is an established risk factor for 
incident cardiovascular disease and progression of heart failure disease state, and 
impairs survival after advanced heart failure therapies (LVAD or HT).1,4,20,21 Select 
studies have demonstrated survival advantages to combined HKT for heart failure 
patients with advanced CKD.22,25 Our data demonstrate two important 
observations. First, it confirms that patients with advanced CKD (stage 4 and 5) 
confer a mortality benefit from combined HKT. Second, patients supported with 
LVAD therapy who have advanced CKD (stages 4 or 5) who receive combined 
HKT have a 2-year survival rate comparable to those who do not have advanced 
CKD who receive isolated HT and patients who receive HKT without prior LVAD 
therapy, and numerically higher survival than those patients with advanced CKD 
who receive HT alone.  
UNOS data reported that between 2008 and 2013, the era encompassing 
continuous-flow LVAD therapy and the present research, a total of 370 patients 
received HKT, among whom 57 (15.4%) patients where supported with LVAD 
therapy; our program has performed combined HKT on 23 patients, among whom 
8 (34.8%) were supported with LVAD prior to HKT. Only one prior investigation 
has evaluated the feasibility and clinical outcomes of patients supported with 
LVAD therapy who received HKT.23 Our cohort is larger, extends follow-up beyond 
6 months and demonstrates comparable survival outcomes to a contemporary 
cohort of patients who underwent either HKT without LVAD therapy or HT with 
advanced CKD. The retrospective and single-center nature of this investigation is 
associated with selection bias. However, patients who received HKT irrespective 
of LVAD therapy in our program were similar with the exception of female gender; 
which was more common among those not receiving LVAD therapy, likely 
reflecting the known bias associated with LVAD treatment and body size. 
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Conclusions 
Patients supported with LVAD therapy who demonstrate advanced CKD (stages 4-
5) have worse 24-month post-HT survival compared with those with less-advanced 
CKD (stages 1-3). Combined HKT after LVAD support is feasible and confers 
comparable 24-month survival compared with HKT without prior LVAD therapy. 
Our study supports combined HKT for select LVAD patients with advanced CKD 
(stages 4-5).
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